---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-269398"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:45:58.742234+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Karyopharm pauses endometrial cancer program update; in talks with FDA about Phase 3 trial

## Summary
- Company in discussions with FDA regarding evolving treatment landscape for endometrial cancer and its impact on Phase 3 XPORT-EC-042 trial.
- Karyopharm will not discuss endometrial cancer program at Piper Sandler conference on Dec 3, 2024.
- Company intends to provide update on endometrial cancer program after FDA discussion.

## SEC filing metadata
- accession: 0001193125-24-269398
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312524269398/0001193125-24-269398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312524269398/d916753d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-269398
- JSON: https://secwatch.observer/filing/0001193125-24-269398.json
- Plain text: https://secwatch.observer/filing/0001193125-24-269398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.